Rexahn Pharmaceuticals, Inc. (NYSE:RNN)
Rexahn Pharmaceuticals, Inc. (NYSE:RNN) represented a move of 0 percent or $0.04 per share and closed its previous day trading session at $1.1. 0 Shares were traded in the last trading session with an Average Volume of 195.59 Million Shares. The stock currently has a Market Capitalization of 42.06 Million.
REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy.
The stock traded between $1.03 and $2.70 over 1-Year time period showing its price to sales ratio of 0. Rexahn Pharmaceuticals, Inc. (NYSE:RNN) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-17.49 and 200-Day Simple Moving Average of $-31.74. Its Price to Free Cash Flow is 0 and Price to Book of 5.5.
Analyst’s recommended the stock as 1.8 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Rexahn Pharmaceuticals, Inc. (NYSE:RNN) reported its Actual EPS of $-0.17/share. The analysts offering Earnings Estimates for the company were believing that Rexahn Pharmaceuticals, Inc. could bring EPS of $-0.17/share. The difference between Actual EPS and Estimated EPS was 0 Percent. Thus showing an Earnings Surprise of 0 Percent.
Sophiris Bio, Inc. (NASDAQ:SPHS)
In the last trading session, Sophiris Bio, Inc. (NASDAQ:SPHS) added its value by 0% closing at the price of $2.1. The stock currently has market capitalization of 62.89 Million, with average volume of 241.02 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Sophiris Bio, Inc. (NASDAQ:SPHS) is showing beta of 1.91. This particular value of beta suggests that Sophiris Bio, Inc. (NASDAQ:SPHS) has historically moved 191% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Sophiris Bio, Inc. (NASDAQ:SPHS) is at $-0.54.
The stock currently has RSI of 52.59. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Sophiris Bio Inc. operates as a biopharmaceutical company. The Company is developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate). It has operations based in San Diego. Sophiris Bio Inc. is based in Canada.
Sophiris Bio, Inc. (NASDAQ:SPHS) topped its 52-week high price of $4.05 on 05/31/18 and 52-Week Low Price of $1.72 on 11/15/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 6.95% and monthly volatility of 7.72% respectively.